Abstract
Depending on the metastatic pattern involved, therapeutic approaches in metastatic malignant melanoma are primarily focused on the surgical reduction of tumor masses (if solitary or operable) and palliation of disseminated disease. Despite major efforts to improve the efficacy of cytotoxic drug regimens, longterm survival or even cure is usually almost unfeasible once dissemination of disease has commenced. However, the administration of bi-omodulatory and/or immunomodulatory compounds has prompted broad investigational efforts since it had been demonstrated that neoplastic tumor growth can be modulated. Among others, the anti-hormonal agent Tamoxifen (TAM) has manifold biological properties that are approached to be exploited in cancer therapy [1]. Previous reports on combination therapy together with cytotoxic agents revealed promising palliative results exceeding those obtained by cytotoxic treatment only [8–12]. The investigational ITBCD protocol described here deals with sequential combination of TAM together with Interferon-α-2b preceding cytotoxic combination chemotherapy consisting of BCNU, DTIC, and Cisplatin. The modalities used are arranged sequentially (phase 1–3) and superimposed synergistically thus exerting overlapping biological effects (phase 1: « Induction »; phase 2: « Priming »; phase 3: « Cytotoxic »). They are outlined to pharmacodynamically prime melanoma metastasis and thus augment the efficacy of cytotoxic compounds used.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Buckley MMT, Goa KL (1989) Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37: 451–490
Greenberg D, Carpenter C, Messing R (1987) Calcium channel antagonist properties of the antineoplastic antiestrogen Tamoxifen in the PC12 neurosecretory cell line. Cancer Res 47: 70–74
Kaye SB (1990) Reversal of multidrug resistance. Cancer Treat Rev 17 (suppl A): 37–43
Sica G, Iacopino F, Robustelli della Cuna G (1988) Recombinant α-2b Interferon (intron A) modifies steroid receptor level, inhibits cell proliferation and promotes the antiproliferative activity of Tamoxifen in a human breast cancer cell line. 6th Med Congr Chemother (MOC), Taormina, Italy 1988, May 22–27
Van den Berg HW, Leahey WJ, Lynch M, Clarke R, Nelson J (1987) Recombinant human Interferon-α: increases oestrogen receptor expression in human breast cancer cells (ZR-75–1) and sensitizes them to the anti-proliferative effects of Tamoxifen. Br J Cancer 55: 255–257
Josui K, Abe O, Kubota T, Koh J, Yamada Y, Asanuma F (1990) Interferon-α increases estrogen receptors of human breast carcinoma xenografts in nude mouse and enhances the antiproliferative activity of Tamoxifen. J Cancer Res Clin Oncol 116 (Suppl): 456
Creagan ET, Ingle JN, Ahmann DL, Green SJ (1982) Phase II study of high-dose Tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. Cancer 49: 1353–1354
Del Prete SA, Maurer LH, O’Donnell J, Jackson Forcier R, Le Marbre P (1984) Combination chemotherapy with Cisplatin, Carmustine, Dacarbazine and Tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403–1405
McClay EF, Mastrangelo MJ, Bellet RE (1987) Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71: 465–469
McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D (1989) The importance of Tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63: 1292–1295
Berd D, McLaughlin CJ, Hart E, Wiebe VJ, Mastrangelo MJ, Bellet RE, De Gregorio MW (1991) Short course high-dose Tamoxifen (TAM) with cytotoxic chemotherapy for metastatic melanoma. Proc ASCO 10, 291: 1016
McClay EF, Albright K, Jones J, Christen R, Howell SB (1991) Modulation of Cisplatin (DDP) sensitivity by Tamoxifen (TAM) in human malignant melanoma. Proc ASCO 10, 191: 1017
Voigt H, Claßen R, Ramaker J, Rauschning W (1993) Tamoxifen plasma and tissue concentrations during ITBCD biochemotherapy for metastatic melanoma (in preparation)
Epstein L, Benz CC, Doty E (1987) Synergistic antiproliferative effects of Interferon-α and Tamoxifen on human breast cancer cells in vitro. J Clin Res 35, 1: P 196A
Edwards BS, Merritt JA, Fuhlbrigge RC, Borden EC (1985) Low doses of Interferon-α result in more effective clinical natural killer cell activation. J Clin Invest 75: 1908–1913
Kirkwood JM (1991) Studies of Interferons in the therapy of melanoma. Sem Oncol 18 (suppl 7): 83–90
Von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional Interferon-α in advanced malignant melanoma. Cancer 61: 1071–1074
Voigt H, Bassermann R (1991) Intralesional (I.L.) Interferon-α-2b (rIFN-α-2b) as adjunct to the palliative management for advanced malignant melanoma. 35th Ann Clin Conf & 24th Ann Spec Pathol Progr «Advances in the biology and clinical management of melanoma», Houston, Texas 1991, November 20–23
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag France
About this paper
Cite this paper
Voigt, H., Claßen, R., Ramaker, J. (1994). Tamoxifen-augmented biochemotherapy (Interferon-α-2b, Tamoxifen, BCNU, CDDP, DTIC) for malignant melanoma. In: Banzet, P., Holland, J.F., Khayat, D., Weil, M. (eds) Cancer Treatment An Update. Springer, Paris. https://doi.org/10.1007/978-2-8178-0765-2_133
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0765-2_133
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0767-6
Online ISBN: 978-2-8178-0765-2
eBook Packages: Springer Book Archive